Neovasc (NVCN) Reports Q3 Loss of $0.70, Revenues Miss

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. AMGN
3. DOX
4. BKNG
5. DUOL
6. ANET
7. SWKS
8. XYZ
9. CVS
10. FISV

Go back to Neovasc (NVCN) Reports Q3 Loss of $0.70, Revenues Miss

Neovasc Announces Third Quarter 2018 Financial Results

November 14, 2018 4:00 PM EST

NASDAQ, TSX: NVCN

FDA has granted Breakthrough Device designation to the Neovasc Reducer (the "Reducer") for the treatment of refractory angina Reducer implanted in 100th patient in Germany Tiara (the "Tiara") featured in live case at the 32nd Annual European Association for Cardio-Thoracic Surgery (EACTS) Meeting in Milan Peer-reviewed article on Tiara cases published in Circulation: Cardiovascular Interventions Regained compliance with the Nasdaq minimum bid price rule

VANCOUVER, Nov. 14, 2018 /PRNewswire/ - Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN TSX:... More